| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.6 | 8.1 |
| Gross profit | 12.1 | 3.5 |
| Net income | -32.7 | -19.5 |
| EPS (diluted, $ a share) | $-0.50 | $-0.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +141.6% |
|---|---|
| Gross margin | 61.7% |
| Operating margin | -162.9% |
10-Q filed with the SEC, NASDAQ: SENS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Senseonics Holdings, Inc.: key numbers
- Share price
- $10.90Close, Nov 16
- Market cap
- $597M
- Shares outstanding
- 54.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Industrial Instruments For Measurement, Display, and ControlSIC 3823
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Senseonics Holdings, Inc.
All →Senseonics Holdings Director Douglas A. Roeder Buys $176K of Stock
Douglas A. Roeder, Director, bought 17,041 shares of Senseonics Holdings, Inc. at $10.32 a share, worth $176K in total on Nov 13, 2026. Shares held after the trade: 189,712 (+9.9%).
- Value
- $176K
- Shares
- 17,040
- Price
- $10.32
- Role
- Director
- Holding change
- +9.9%
- Trade date
- Nov 13, 2026
Senseonics Holdings Financial Results
Senseonics reported Q3 2026 revenue of $19.6 million, a 140% increase year-over-year, driven by strong U.S. commercial execution of the Eversense 365 CGM system. The company raised its full-year 2026 revenue guidance to $68-$70 million and improved its gross margin to 62%. Management highlighted the expansion of the EON Care network and a new strategic partnership with Beta Bionics for insulin pump integration.
- Term
- Q3 2026
“Our approximately 140% year-over-year revenue growth in Q3 reflects the progress we are making in executing our commercial strategy and driving increased awareness and demand for Eversense 365. Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins.”
Tim Goodnow, PhD, President and Chief Executive Officer
“Multiple initiatives to expand awareness and access create opportunities to bring Eversense to patients and prescribers we had not previously reached. As EON Care grows, we can extend our direct-to-consumer and health care provider outreach into additional markets with an insertion option already in place.”
Brian Hansen, Chief Commercial Officer